Для того, чтобы увидеть эту страницу на русском языке, нажмите здесь

Click here for Russian

Welcome Word from Robert Rosen, CEO Selecta Russia

At Selecta Biosciences, our vision is to develop and bring to the market an entirely new class of targeted vaccines utilizing our proprietary platform technology of Synthetic Vaccine Particles (SVP™). Our technology is capable of activating robust immune responses both for prophylactic and therapeutic applications and also has the unique capability of inducing antigen-specific immune tolerance. The diversity of our platform enables us to address a wide range of diseases including cancer, autoimmune diseases, allergies, infectious diseases, and neuroscience.  

We are thrilled to expand our business in Russia and proud of the progress we have made – and we will continue to make progress toward our strategic vision. We recognize and value the importance of our team members and we seek to recruit those who share our passion and are inspired by the potential of our technology to make a difference for patients. We invite you to learn more about Selecta, our people, our technology, and the many possibilities for partnerships and collaborations.  

About Selecta Russia

Selecta Russia is a wholly-owned subsidiary of Selecta Biosciences, Inc.

The company mission is to build a robust pipeline of Synthetic Vaccine Particles (SVP™) vaccines for the global marketplace. Our activities in Russia support Selecta Biosciences' goals of expanding its vaccine portfolio and accelerating its clinical development, while recognizing the specific requirements of Russian patients. Selecta Russia R&D programs are developed in close coordination with Selecta in Boston and include prophylactic and therapeutic vaccines in a wide range of therapeutic areas including infectious diseases, cancer, and addiction.

Throughout 2012, Selecta Russia will build a full-fledged R&D facility and initiate work on several programs. Initially, Selecta Russia will produce laboratory supplies with the longer term objective of operating GLP and GMP approved facilities for its SVP™ platform.

The establishment of Selecta in Russia is aligned with the Russian Government's Pharma 2020 efforts to support local companies to develop and produce innovative medicines and provide access to the latest therapies for the benefit of patients both in Russia and worldwide.

Russian and international companies and scientific institutions, who are interested in collaborating with us, are welcome to contact us under (bd@selectabio.com).

Selecta Russia is recruiting highly motivated and experienced individuals with backgrounds in chemistry, immunology or related fields. Our new employees will work in modern laboratories and be in close contact with Selecta's staff in Boston. Senior staff will be initially trained in Boston and the entire team will have the opportunity to learn from leading experts in the fields of medicinal nanotechnology and immunology.